Tenaya’s TN-301 Outperforms Givinostat in Duchenne Muscular Dystrophy Preclinical Trials
Event summary
- Tenaya Therapeutics presented preclinical data at MDA 2026 showing TN-301 improved muscle function and corrected cardiomyopathy drivers in Duchenne muscular dystrophy (DMD) models.
- TN-301 outperformed the approved pan-HDAC inhibitor givinostat in restoring muscle performance to wild-type levels in mdx mice.
- TN-301 demonstrated favorable changes in gene expression, reduced muscle cell injury, and corrected calcium handling abnormalities in human DMD iPSC-cardiomyocytes.
- Tenaya plans to advance TN-301 toward Phase 2 clinical development for HFpEF and DMD indications.
The big picture
Tenaya Therapeutics’ preclinical data for TN-301 highlights a potential breakthrough in treating Duchenne muscular dystrophy, addressing both skeletal muscle atrophy and cardiac decline. The company’s highly selective HDAC6 inhibitor outperformed existing treatments, positioning Tenaya as a key player in the rare disease and cardiovascular therapy markets. This development comes at a time when there is growing interest in targeted therapies for genetic heart diseases, driven by advancements in gene editing and small molecule inhibitors.
What we're watching
- Clinical Translation
- Whether TN-301’s preclinical success in DMD models will translate into comparable efficacy and safety in human trials.
- Regulatory Pathway
- The pace at which Tenaya can secure regulatory approvals for TN-301, given its differentiated mechanism of action.
- Competitive Positioning
- How TN-301’s superior performance against givinostat will impact Tenaya’s market positioning in the DMD and HFpEF spaces.
Our editorial coverage:
Related topics